SCHEMBL314852

SCHEMBL314852

COc1ccc(-c2nnc3n2-c2ccccc2SCC3)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
HPGD P15428 3/20 0.56
OXTR P30559 2/20 0.45
TSHR P16473 3/20 0.44
GLA P06280 1/20 0.44
MAPT P10636 4/20 0.42
AVPR2 P30518 2/20 0.41
AVPR1A P37288 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 3/20 0.40
GAA P10253 2/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HCRTR1 O43613 1/20 0.39
USP2 O75604 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313900 0.86 HPGD (0.48) ALDH1A1HPGDTSHRAVPR2AVPR1A
SCHEMBL314376 0.76 ALDH1A1 (0.46) ALDH1A1HPGDOXTRTSHRGLA
SCHEMBL314375 0.76 ALDH1A1 (0.46) ALDH1A1HPGDOXTRTSHRGLA
SCHEMBL314377 0.76 ALDH1A1 (0.46) ALDH1A1HPGDOXTRTSHRGLA
SCHEMBL12841365 0.67 TSHR (0.62) HPGDTSHRAVPR2AVPR1ASMN1; SMN2
SCHEMBL314776 0.66 TSHR (0.40) ALDH1A1HPGDOXTRTSHRGLA
SCHEMBL17295000 0.65 AVPR2 (0.60) ALDH1A1HPGDOXTRTSHRGLA
SCHEMBL10627154 0.65 OXTR (0.88) ALDH1A1HPGDOXTRTSHRGLA
SCHEMBL7322559 0.63 OXTR (0.44) ALDH1A1HPGDOXTRTSHRGLA
SCHEMBL2851701 0.62 HPGD (0.72) ALDH1A1HPGDTSHRMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 ALDH1A1 2295/4885HPGD 2258/4885OXTR 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.